Abstract
Polo-like kinases (PLKs) are a family of serine/threonine kinases that play crucial roles in multiple stages of mitosis. PLK1 is the most studied member of the family. It is overexpressed in a wide spectrum of cancer types and is a promising target in oncology. Most of PLK1 inhibitors are ATP-competitive. Despite the structural similarities among various kinases, several inhibitors are selective. Some areas of the PLK1 active site are important for selectivity against other kinases. These include a small pocket formed by Leu 132 in the hinge region, a bulky phenylalanine and a small cysteine at the bottom and in the roof of the ATP pocket, respectively, and an unusual concentration of positively charged residues in the solvent-exposed region. Many ATP-competitive inhibitors are heterocyclic systems able to interact with the unique features of the PLK1 binding site. Other inhibitors target regions outside the ATP pocket, such as the substrate binding domain or a hydrophobic pocket, formed when the kinase is in the inactive conformation. An alternative approach to obtain specificity and to overcome drug resistance often associated with kinase inhibitors is the inhibition of the polo-box domain (PBD) of PLK1. The PBD is unique for the family of PLKs and is essential for PLK functions; so it is a useful target for the development of selective and potent inhibitors for clinical uses. In this review some PLK inhibitors are reported, focusing on chemical structures, structure-activity-relationships (SAR) and biological activities. The great potential of these compounds could open promising perspectives. Moreover, a combination of polo-like kinases inhibitors with other anticancer drugs might offer new opportunities for cancer therapy.
Keywords: Antitumor activity, ATP-competitive, inhibitor, polo-box, polo-like kinase, SAR, selectivity, hinge region, thiophene, quinazoline
Current Medicinal Chemistry
Title:Polo-Like Kinases Inhibitors
Volume: 19 Issue: 23
Author(s): L. Garuti, M. Roberti and G. Bottegoni
Affiliation:
Keywords: Antitumor activity, ATP-competitive, inhibitor, polo-box, polo-like kinase, SAR, selectivity, hinge region, thiophene, quinazoline
Abstract: Polo-like kinases (PLKs) are a family of serine/threonine kinases that play crucial roles in multiple stages of mitosis. PLK1 is the most studied member of the family. It is overexpressed in a wide spectrum of cancer types and is a promising target in oncology. Most of PLK1 inhibitors are ATP-competitive. Despite the structural similarities among various kinases, several inhibitors are selective. Some areas of the PLK1 active site are important for selectivity against other kinases. These include a small pocket formed by Leu 132 in the hinge region, a bulky phenylalanine and a small cysteine at the bottom and in the roof of the ATP pocket, respectively, and an unusual concentration of positively charged residues in the solvent-exposed region. Many ATP-competitive inhibitors are heterocyclic systems able to interact with the unique features of the PLK1 binding site. Other inhibitors target regions outside the ATP pocket, such as the substrate binding domain or a hydrophobic pocket, formed when the kinase is in the inactive conformation. An alternative approach to obtain specificity and to overcome drug resistance often associated with kinase inhibitors is the inhibition of the polo-box domain (PBD) of PLK1. The PBD is unique for the family of PLKs and is essential for PLK functions; so it is a useful target for the development of selective and potent inhibitors for clinical uses. In this review some PLK inhibitors are reported, focusing on chemical structures, structure-activity-relationships (SAR) and biological activities. The great potential of these compounds could open promising perspectives. Moreover, a combination of polo-like kinases inhibitors with other anticancer drugs might offer new opportunities for cancer therapy.
Export Options
About this article
Cite this article as:
Garuti L., Roberti M. and Bottegoni G., Polo-Like Kinases Inhibitors, Current Medicinal Chemistry 2012; 19 (23) . https://dx.doi.org/10.2174/092986712802002455
DOI https://dx.doi.org/10.2174/092986712802002455 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chemical Space of FLT3 Inhibitors as Potential Anti-AML Drugs
Recent Patents on Anti-Cancer Drug Discovery Mitigative Effects of a Combination of Multiple Pharmaceutical Drugs on the Survival of Mice Exposed to Lethal Ionizing Radiation
Current Pharmaceutical Biotechnology Interaction of Human Brain Acetylcholinesterase with Cyclophosphamide: A Molecular Modeling and Docking Study
CNS & Neurological Disorders - Drug Targets Histone Deacetylase Inhibitors: An Attractive Strategy for Cancer Therapy
Current Medicinal Chemistry Need to Think Outside Organ-based Diagnosis to Molecular Diagnostics
Applied Clinical Research, Clinical Trials and Regulatory Affairs Natural Compounds as Anticancer Agents Targeting DNA Topoisomerases
Current Genomics Agonists and Antagonists Acting at P2X7 Receptor
Current Topics in Medicinal Chemistry Non-Transferrin Bound Iron - Determination in Biological Material and Clinical Implications
Current Pharmaceutical Analysis Flavonoids in Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry Cyclophosphamide: Time to Say Goodnight and Goodbye?
Current Rheumatology Reviews Association of p53 with Bid Induces Cell Death in Response to Etoposide Treatment in Hepatocellular Carcinoma
Current Cancer Drug Targets Folate Receptor Targeted Liposomes Encapsulating Anti-Cancer Drugs
Current Pharmaceutical Biotechnology Focus on the Multimodal Role of Biomarkers in Breast Cancer
Current Pharmaceutical Design Cytosine Methyltransferases as Tumor Markers
Current Genomics Current Status of Epigenetics and Anticancer Drug Discovery
Anti-Cancer Agents in Medicinal Chemistry Biological Abilities of Rice Bran-Derived Antioxidant Phytochemicals for Medical Therapy
Current Topics in Medicinal Chemistry 1,3,4-Oxadiazole Derivatives as Potential Biological Agents
Mini-Reviews in Medicinal Chemistry Targeting Prostate Cancer Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Advancements in Non-steroidal Antiandrogens as Potential Therapeutic Agents for the Treatment of Prostate Cancer
Mini-Reviews in Medicinal Chemistry Twist-BRD4 Complex: Potential Drug Target for Basal-like Breast Cancer
Current Pharmaceutical Design